Cargando…
Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
BACKGROUND: Metastatic pancreatic cancer (mPC) is a highly lethal malignancy with poorer survival. However, chemotherapy alone was unable to maintain long‐term survival. This study aimed to evaluate the individualized survival benefits of pancreatectomy plus chemotherapy (PCT) for mPC. METHODS: A to...
Autores principales: | Nie, Duorui, Lai, Guihua, An, Guilin, Wu, Zhuojun, Lei, Shujun, Li, Jing, Cao, Jianxiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481362/ https://www.ncbi.nlm.nih.gov/pubmed/34604055 http://dx.doi.org/10.3389/fonc.2021.719253 |
Ejemplares similares
-
Survival analysis and individualized prediction of survival benefit for pancreatic signet ring cell carcinoma: a population study based on the SEER database
por: Nie, Duorui, et al.
Publicado: (2023) -
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020) -
Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
por: Thomas, Quentin Dominique, et al.
Publicado: (2022) -
Nomogram predicts CR-POPF in open central pancreatectomy patients with benign or low-grade malignant pancreatic neoplasms
por: Ouyang, Liu, et al.
Publicado: (2022) -
Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)